{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:25:30Z","timestamp":1707524730653},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,27]]},"DOI":"10.7759\/cureus.28479","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T20:04:02Z","timestamp":1661630642000},"source":"Crossref","is-referenced-by-count":0,"title":["Non-surgical Management of Locally Advanced Basal Cell Carcinoma of the Upper Extremity With Vismodegib"],"prefix":"10.7759","author":[{"given":"Austin R","family":"Swisher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J","family":"Landau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison B","family":"Davila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando A","family":"Davila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caryn","family":"Zagaynov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A","family":"Bobbitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darren S","family":"Leong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander Y","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter T","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-016-0168-2","article-title":"Hepatotoxicity with vismodegib: an MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project","volume":"17","author":"Edwards BJ","year":"2017","unstructured":"Edwards BJ, Raisch DW, Saraykar SS, et al.. Hepatotoxicity with vismodegib: an MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project. Drugs R D. 2017, 17:211-218. 10.1007\/s40268-016-0168-2","journal-title":"Drugs R D"},{"key":"ref2","unstructured":"NCCN guidelines for patients basal cell skin cancer. (2022). Accessed. August 6, 2022: https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/basal-cell-patient-guideline.pdf."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S101330","article-title":"Spotlight on vismodegib in the treatment of basal cell carcinoma: an evidence-based review of its place in therapy","volume":"10","author":"Apalla Z","year":"2017","unstructured":"Apalla Z, Papageorgiou C, Lallas A, et al.. Spotlight on vismodegib in the treatment of basal cell carcinoma: an evidence-based review of its place in therapy. Clin Cosmet Investig Dermatol. 2017, 10:171-177. 10.2147\/CCID.S101330","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00400-z","article-title":"Intralesional methotrexate for the treatment of advanced keratinocytic tumors: a multi-center retrospective study","volume":"10","author":"Gualdi G","year":"2020","unstructured":"Gualdi G, Caravello S, Frasci F, et al.. Intralesional methotrexate for the treatment of advanced keratinocytic tumors: a multi-center retrospective study. Dermatol Ther (Heidelb). 2020, 10:769-777. 10.1007\/s13555-020-00400-z","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjps.2019.06.029","article-title":"Reappraisal of giant basal cell carcinoma: clinical features and outcomes","volume":"73","author":"Oudit D","year":"2020","unstructured":"Oudit D, Pham H, Grecu T, et al.. Reappraisal of giant basal cell carcinoma: clinical features and outcomes. J Plast Reconstr Aesthet Surg. 2020, 73:53-57. 10.1016\/j.bjps.2019.06.029","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11123439","article-title":"A conservative combined laser cryoimmunotherapy treatment vs. surgical excision for basal cell carcinoma","volume":"11","author":"Scurtu LG","year":"2022","unstructured":"Scurtu LG, Petrica M, Grigore M, Avram A, Popescu I, Simionescu O. A conservative combined laser cryoimmunotherapy treatment vs. surgical excision for basal cell carcinoma. J Clin Med. 2022, 11:10.3390\/jcm11123439","journal-title":"J Clin Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers8020022","article-title":"Targeting the sonic hedgehog signaling pathway: review of smoothened and GLI inhibitors","volume":"8","author":"Rimkus TK","year":"2016","unstructured":"Rimkus TK, Carpenter RL, Qasem S, Chan M, Lo HW. Targeting the sonic hedgehog signaling pathway: review of smoothened and GLI inhibitors. Cancers (Basel). 2016, 8:10.3390\/cancers8020022","journal-title":"Cancers (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.02.002","article-title":"Smoothened variants explain the majority of drug resistance in basal cell carcinoma","volume":"27","author":"Atwood SX","year":"2015","unstructured":"Atwood SX, Sarin KY, Whitson RJ, et al.. Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell. 2015, 27:342-353. 10.1016\/j.ccell.2015.02.002","journal-title":"Cancer Cell"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/1758834016653605","article-title":"Hedgehog pathway inhibition in advanced basal cell carcinoma: latest evidence and clinical usefulness","volume":"8","author":"Silapunt S","year":"2016","unstructured":"Silapunt S, Chen L, Migden MR. Hedgehog pathway inhibition in advanced basal cell carcinoma: latest evidence and clinical usefulness. Ther Adv Med Oncol. 2016, 8:375-382. 10.1177\/1758834016653605","journal-title":"Ther Adv Med Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2745","article-title":"Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors","volume":"17","author":"LoRusso PM","year":"2011","unstructured":"LoRusso PM, Rudin CM, Reddy JC, et al.. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011, 17:2502-2511. 10.1158\/1078-0432.CCR-10-2745","journal-title":"Clin Cancer Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic A","year":"2012","unstructured":"Sekulic A, Migden MR, Oro AE, et al.. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012, 366:2171-2179. 10.1056\/NEJMoa1113713","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1956","article-title":"U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma","volume":"19","author":"Axelson M","year":"2013","unstructured":"Axelson M, Liu K, Jiang X, et al.. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clin Cancer Res. 2013, 19:2289-2293. 10.1158\/1078-0432.CCR-12-1956","journal-title":"Clin Cancer Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.06.003","article-title":"Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines","volume":"118","author":"Peris K","year":"2019","unstructured":"Peris K, Fargnoli MC, Garbe C, et al.. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur J Cancer. 2019, 118:10-34. 10.1016\/j.ejca.2019.06.003","journal-title":"Eur J Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0003","article-title":"Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma","volume":"19","author":"Dreno B","year":"2014","unstructured":"Dreno B, Basset-Seguin N, Caro I, Yue H, Schadendorf D. Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma. Oncologist. 2014, 19:790-796. 10.1634\/theoncologist.2014-0003","journal-title":"Oncologist"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00794","article-title":"Follow-up of patients with complete remission of locally advanced basal cell carcinoma after vismodegib discontinuation: a multicenter French study of 116 patients","volume":"37","author":"Herms F","year":"2019","unstructured":"Herms F, Lambert J, Grob JJ, et al.. Follow-up of patients with complete remission of locally advanced basal cell carcinoma after vismodegib discontinuation: a multicenter French study of 116 patients. J Clin Oncol. 2019, 37:3275-3282. 10.1200\/JCO.18.00794","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28080","article-title":"Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma","volume":"12","author":"Doan HQ","year":"2021","unstructured":"Doan HQ, Chen L, Nawas Z, Lee HH, Silapunt S, Migden M. Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma. Oncotarget. 2021, 12:2089-2100. 10.18632\/oncotarget.28080","journal-title":"Oncotarget"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.04.013","article-title":"Efficacy of vismodegib for the treatment of orbital and advanced periocular basal cell carcinoma","volume":"207","author":"Eiger-Moscovich M","year":"2019","unstructured":"Eiger-Moscovich M, Reich E, Tauber G, et al.. Efficacy of vismodegib for the treatment of orbital and advanced periocular basal cell carcinoma. Am J Ophthalmol. 2019, 207:62-70. 10.1016\/j.ajo.2019.04.013","journal-title":"Am J Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13820","article-title":"Vismodegib for preservation of visual function in patients with advanced periocular basal cell carcinoma: The VISORB trial","volume":"26","author":"Kahana A","year":"2021","unstructured":"Kahana A, Unsworth SP, Andrews CA, et al.. Vismodegib for preservation of visual function in patients with advanced periocular basal cell carcinoma: The VISORB trial. Oncologist. 2021, 26:e1240-e1249. 10.1002\/onco.13820","journal-title":"Oncologist"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/2036361318772938","article-title":"Giant morphea-form basal cell carcinoma of the umbilicus: successful debulking with vismodegib","volume":"10","author":"Orduz Robledo M","year":"2018","unstructured":"Orduz Robledo M, Lebas E, Reginster MA, Baghaie M, Groves S, Nikkels AF. Giant morphea-form basal cell carcinoma of the umbilicus: successful debulking with vismodegib. Rare Tumors. 2018, 10:2036361318772938. 10.1177\/2036361318772938","journal-title":"Rare Tumors"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/12034754211051234","article-title":"Real-world experience of vismodegib in advanced basal cell carcinoma at a Canadian Cancer Center","volume":"26","author":"Tong J","year":"2022","unstructured":"Tong J, Mitchell B, Roth K, Logan D, Ernst S. Real-world experience of vismodegib in advanced basal cell carcinoma at a Canadian Cancer Center. J Cutan Med Surg. 2022, 26:143-148. 10.1177\/12034754211051234","journal-title":"J Cutan Med Surg"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100844","article-title":"Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: first results of a multicenter, open-label, phase 2 trial (VISMONEO study): neoadjuvant vismodegib in locally advanced basal cell carcinoma","volume":"35","author":"Bertrand N","year":"2021","unstructured":"Bertrand N, Guerreschi P, Basset-Seguin N, et al.. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: first results of a multicenter, open-label, phase 2 trial (VISMONEO study): neoadjuvant vismodegib in locally advanced basal cell carcinoma. EClinicalMedicine. 2021, 35:100844. 10.1016\/j.eclinm.2021.100844","journal-title":"EClinicalMedicine"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.11.002","article-title":"Vismodegib for giant, locally advanced, basal cell carcinoma and its complex position in clinical practice","volume":"5","author":"Koekelkoren FH","year":"2019","unstructured":"Koekelkoren FH, Roodbergen SL, Baerveldt EM, et al.. Vismodegib for giant, locally advanced, basal cell carcinoma and its complex position in clinical practice. JAAD Case Rep. 2019, 5:267-270. 10.1016\/j.jdcr.2018.11.002","journal-title":"JAAD Case Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/pde.13610","article-title":"Use of vismodegib for the treatment of multiple basal cell carcinomas in a patient with xeroderma pigmentosum","volume":"35","author":"Soura E","year":"2018","unstructured":"Soura E, Plaka M, Dessinioti C, Chasapi V, Stefanaki C, Antoniou C, Stratigos A. Use of vismodegib for the treatment of multiple basal cell carcinomas in a patient with xeroderma pigmentosum. Pediatr Dermatol. 2018, 35:e334-e336. 10.1111\/pde.13610","journal-title":"Pediatr Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/SAP.0000000000000452","article-title":"The impact of neoadjuvant hedgehog inhibitor therapy on the surgical treatment of extensive basal cell carcinoma","volume":"74","author":"Ching JA","year":"2015","unstructured":"Ching JA, Curtis HL, Braue JA, et al.. The impact of neoadjuvant hedgehog inhibitor therapy on the surgical treatment of extensive basal cell carcinoma. Ann Plast Surg. 2015, 74:S193-S197. 10.1097\/SAP.0000000000000452","journal-title":"Ann Plast Surg"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14650","article-title":"Reflectance confocal microscopy identification of subclinical basal cell carcinomas during and after vismodegib treatment","volume":"32","author":"Couzan C","year":"2018","unstructured":"Couzan C, Cinotti E, Labeille B, Vercherin P, Rubegni P, Cambazard F, Perrot JL. Reflectance confocal microscopy identification of subclinical basal cell carcinomas during and after vismodegib treatment. J Eur Acad Dermatol Venereol. 2018, 32:763-767. 10.1111\/jdv.14650","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/107497-non-surgical-management-of-locally-advanced-basal-cell-carcinoma-of-the-upper-extremity-with-vismodegib","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:50:28Z","timestamp":1707508228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/107497-non-surgical-management-of-locally-advanced-basal-cell-carcinoma-of-the-upper-extremity-with-vismodegib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,27]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.28479","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,27]]}}}